共 75 条
[1]
Bruns C(2002)SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile Eur J Endocrinol 146 707-716
[2]
Lewis I(2010)Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, Phase II trial J Clin Endocrinol Metab 95 2781-2789
[3]
Briner U(2007)The effects of pasireotide (SOM230) on health-related quality of life in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR J Clin Oncol 25 abst-688
[4]
Meno-Tetang G(2012)Tolerability and dose-proportional pharmacokinetics of pasireotide administered as a single dose or two divided doses in healthy male volunteers: a single-center, open-label, ascending-dose study Clin Ther 34 677-1027
[5]
Weckbecker G(2012)Pasireotide (SOM230), a novel multi-receptor-targeted somatostatin analogue, is well tolerated when administered as a continuous 7-day subcutaneous infusion in healthy male volunteers J Clin Pharmacol 52 1017-80
[6]
Petersenn S(2005)Pharmacokinetic–pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly Clin Pharmacol Ther 78 69-79
[7]
Schopohl J(2012)A first-in-man study to evaluate the safety, tolerability and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers Drug Des Devel Ther 6 71-558
[8]
Barkan A(2012)Effect of hepatic impairment on the pharmacokinetics of pasireotide (SOM230): results from a multicenter Phase I study J Clin Pharmacol 52 552-370
[9]
Mohideen P(1920)An analysis of the time-relations of electrocardiograms Heart 7 353-541
[10]
Colao A(2010)Accelerator mass spectrometry-enabled studies: current status and future prospects Bioanalysis 2 519-413